WELCOME TO THE BRITISH ASSOCIATION FOR THE STUDY OF THE LIVER
Thank you for supporting BASL2020. Presentations from the Virtual Annual Meeting are now available through the OnAir events portal using your registration log on.
BASL2020 VIRTUAL ANNUAL MEETING
21st - 23rd September - registration CLOSED
Thank you to our members and to the liver community who supported BASL2020. Presentations from the Virtual annual meeting are now available to view through the OnAir meeting portal. Registrants should use their registration log on details to access. Provisional dates for BASL2021 are Tuesday 21st - Friday 24th September – these dates will be confirmed as soon as possible.
BASL VIRTUAL ANNUAL MEETING
BASL AND BASL SUB-GROUPS
The British Association for the Study of the Liver is a multi-disciplinary society with around 900 members composed of interested individuals from clinical medicine, clinical and basic research and allied professions.
British Liver Nurses' Association is a professional nursing organisation aiming to develop knowledge and understanding of liver disease, in order to improve the quality of patient care.
The British Viral Hepatitis aims to improve the management and study of patients with chronic viral liver disease, bringing together UK hepatologists, gastroenterologists, infectious disease physicians, virologists and interested epidemiologists.
The BLTG (British Liver Transplant Group) was launched in 2014 to represent the professional interests of liver transplantation in the UK and promote strategic and academic development. The BLTG will foster close relationships with BTS (British Transplant Society) and LICAGE (Liver Intensive Care Group of Europe) and will build on the role of the UK and Ireland Annual Meeting by delivering structure and authority to the group.
Is a professional pharmacy organisation aiming to develop knowledge and understanding of liver disorders including viral hepatitis, in order to improve the quality of patient care, through medicines optimisation, collaborative and multi-disciplinary working and promoting patient-focused research.
HCC UK is a multi-disciplinary organisation aiming to promote collaboration in research, education and clinical service development for primary liver cancer. We bring together leading oncologists, liver surgeons, hepatologists, basic scientists, radiologists, pathologists and specialist nurses to lead improvement in the quality of patient care.
IQILS accreditation – quality lead roleRead more
The Royal College of Physicians’ Accreditation Unit is seeking to appoint a quality lead to take responsibility for the level one submissions of services working towards full accreditation and supporting services to level 2. The post holder will represent IQILS and support the development of the programme and increase awareness and engagement among Liver services.
This is an exciting and varied role suitable for a consultant hepatologist. The time commitment is 0.5 PA per week. The role description can be found on the IQILS website: https://www.iqils.org/CMS/AllNews.aspx
If you are interested in this role, please send your CV and a supporting statement of no more than 2 pages outlining how you meet the person specification to email@example.com by the closing date.
Please contact the IQILS manager, Madeline Bano at firstname.lastname@example.org if you have any questions or would like an informal discussion about the role.
Applications will close at midnight on Sunday 8 November 2020. Interviews will be held in the morning of Thursday 19 November.
The Royal College of Physicians (RCP) believes that equality of opportunity is fundamental in whatever way individuals become involved with the RCP, whether as physicians, physicians-in-training or staff. It welcomes and actively seeks to recruit people to its activities regardless of race, religion, ethnic origin, disability, age, gender and sexual orientation. The RCP aims to reflect the diversity of its members in all its committee, senior roles and staff.
Patients with cirrhosis at increased risk of death from COVID-19, study findsRead more
An international study led by researchers at Oxford University Hospitals NHS Foundation Trust has shown that patients with cirrhosis are at increased risk of dying as a result of COVID-19.
The study, published in the Journal of Hepatology, found that mortality from COVID-19 was particularly high among patients with more advanced cirrhosis (called Childs-Pugh B or C cirrhosis) and those with alcohol-related liver disease.
The study was a collaboration between scientists at the Oxford Liver Unit, based at Oxford’s John Radcliffe Hospital, and colleagues at the University of North Carolina (USA), and was supported by the European Association for the Study of the Liver (EASL)
The paper presented data on over 1,300 patients from 29 different countries and compared COVID-19 outcomes between patients with and without liver disease.
“Our study confirms that severity of liver disease is closely associated with poor outcomes from COVID-19, with cirrhosis patients being at significantly increased risk of death,” said Dr Thomas Marjot, who leads the study alongside Professor Eleanor Barnes of the University of Oxford’s Nuffield Department of Medicine.
“Given the huge global burden of cirrhosis, with an estimated 112 million people affected, and the resurgence of the virus in many areas of the world these findings have far-reaching implications for how we manage patients with liver disease during the pandemic. This includes the need to consider enhanced protection and social distancing for patients with advanced cirrhosis,” Dr Marjot explained.
The study found that mortality among patients with cirrhosis was 32%, compared with 8% in those without. However, the risk of mortality increased in those with more advanced forms of cirrhosis, rising as high as 51% in those in the most severe category. Other risk factors for death included advancing age and alcohol-related liver disease.
The majority of deaths in cirrhosis patients (71%) were from respiratory failure caused by COVID-19. The virus also seemed to cause a deterioration in liver function, with patients developing complications such as ascites or encephalopathy even in the absence of typical respiratory symptoms of COVID-19.
This work follows a recent publication from the same group in The Lancet Gastroenterology & Hepatology which showed that liver transplant recipients did not appear to be at increased risk of death from the virus.
Dr Andrew Moon at The University of North Carolina said: “This study nicely compliments our findings in patients with prior liver transplantation. In contrast to the presence of advanced cirrhosis, having a liver transplantation was not associated with increased risk of death from COVID-19. This suggests that we should aim to continue liver transplant services during the pandemic wherever possible.”
Professor Thomas Berg, EASL Vice-Secretary General and Head of the Division of Hepatology at Leipzig University Medical Centre in Germany, said: “The findings from this large registry study are very relevant to clinicians and patients worldwide, as we continue to optimise liver disease management during the pandemic.
“These results are timely and reinforce the recommendations made in the joint Position Papers by EASL and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) published in JHEP Reports, which offer guidance on how to approach patients with different types and stages of liver disease.”
Roy Probert, Senior Communications Manager
Mobile: 07341 115585
The effect of lockdown on patients with alcohol-related liver disease: a national service evaluationRead more
Many people have been consuming more alcohol during lockdown, especially those with hazardous or harmful drinking behaviour. Anecdotal observations suggest an increase in the number and severity of admissions of patients with alcohol-related liver disease (ArLD) since lockdown was implemented with more patients presenting with advanced disease including variceal haemorrhage and alcoholic hepatitis. The ArLD Special Interest Group aims to perform a systematic national service evaluation of ArLD hospital episodes to determine whether the number of ArLD patients and the severity of their disease is different post-lockdown compared to a similar period in 2019. Working in collaboration with Public Health colleagues, this information will be combined with a national dataset to help us understand the effect of lockdown on our vulnerable patient group and to plan alcohol services at a local and national level.
We need your help to contribute data from your Trust. We are using a validated Excel-based tool to identify eligible patients and a simple Excel data collection tool. An evaluation lead and any other assistant (e.g. specialty trainee) at each participating centre will be recognised as co-authors in any publications that arise from this evaluation.
To register your interest in participating in this national service evaluation and to receive further details, please email me at email@example.com .
Thank you for your support,
Dr Ashwin Dhanda, BASL ArLD SIG lead
Annual call for topics open - UK NSC - closes midnight December 2020Read more
The UK National Screening Committee (UK NSC) is welcoming you to take part in the 5th ‘Annual Call for New Topics’. This is an opportunity for you to propose a national screening programme for a condition not yet considered by the UK NSC.
If you have an idea for a proposal, then please follow this link to be taken to the guidance:
Please ensure you read through it carefully and use the template submission form. This will help you through the various requirements of a proposal.
The deadline for submissions is midnight, Sunday 6th December 2020.
UK National Screening Committee
Public Health England hosts the UK National Screening Committee
BSG - BASL Decompensated Cirrhosis Discharge Bundles 25.8.2020Read more
Download the BSG - BASL Decompensated Cirrhosis Discharge bundle checklists below:
The third Workshop of the Liver Regenerative Medicine Network is being planned for Thursday 29th October 2020 at the Institute of Hepatology London.
The aim of the Network is to provide a platform for the Liver Regenerative Medicine research community and facilitate inter/multidisciplinary collaboration across the London Universities and Institutes. The half-day Workshop will highlight the current research in hepatic regenerative medicine and tissue engineering, including cell therapy, organoids, organ-on-a-chip, bio-artificial hepatic systems, bioreactors, biomaterials, cancer modelling and stem cell biology.
The meeting will include two Keynote Sessions and two Bright Sparks Sessions with shorter talks.
Download a programme here: Download LLRM workshop prog_Oct 2020.pdf
Further details can be found on the official webpage for the Workshop here > https://www.liver-research.org.uk/newsletter/conferences-meetings.html
To register please contact Dr Luca Urbani by e-mail at firstname.lastname@example.org .
On behalf of the Cambridge Liver Unit you are invited to register for the Annual Liver Symposium on Friday the 6th November.
Time: 10:00 - 16:15
The meeting is Free to attend and includes a parallel nurses forum from 10:00 - 12:30.
Register by clicking > here or clicking the link within the programme below.
Once you have registered you will receive the Zoom links to the meeting nearer the time and we look forward to welcoming you on the day.
Please contact CambridgeLiverSymposium@addenbrookes.nhs.uk for more information or if you have any questions.
Title: RCPE Symposium: Gastroenterology
Date: Wednesday 18 November 2020
Venue: Royal College of Physicians of Edinburgh
Topics: Optimising outpatient capacity // Tackling Scotland’s alcohol problem - doing what works // New frontier; Artificial intelligence; Eosinophilic oesophagitis; Endoscopic management of early luminal cancers // Interactive case discussions
Save the Date
The next meeting of the Wilson's Disease Group will take place on Friday 20th November from 09:00 - 13:00 via Zoom.
A programme will follow shortly.
To register for the meeting, please contact Kim@basl.org.uk .
Save the Date
The next meeting of the Portal Hypertension SIG will take place as a webinar on Thursday 26th November from 13:00 - 17:00.
We have some top speakers including Professor Guru Aithal, Professor William Rosenberg and Dr Debbie Shawcross.
Registration will open soon and if you have any questions please contact email@example.com .